Latest news with #GRIN
Daily Mail
21-04-2025
- Business
- Daily Mail
Beauty experts reveal the biggest recession indicator trends, from DIY extensions to spray tans
Experts have noted signs that a recession is coming, whether it's people spending less money at strip clubs or Americans falling behind on car payments at record rates. There are fashion and beauty signs that only Gen Z and millennial women have spotted indicating an upcoming economic downturn. Some women have noted that clothing seems to be cheaper and coal mining inspired, comparing it to what characters wore in District 12 in The Hunger Games, which was inspired by Appalachia. Others have noticed that more low-key hairstyles that don't require expensive products and upkeep are on the rise, including natural, frizzy hair. Now, Megan Vasquez, a beauty influencer marketing expert at GRIN, has pointed out multiple indications that Gen Z and millennial women are preparing for an economic downtick. Megan, based in Los Angeles, has found that 'people are stretching time between salon visits with lower maintenance options.' 'When areas of life feel uncertain or restricted, beauty remains a form of control and comfort,' Megan said. Amid President Donald Trump 's tariffs, these are the signs that women are looking to save money on pricey beauty treatments. 'As tariffs begin to impact beauty, prices will shift, but habits will shift as well,' Megan warned. Recession brunette is one of the trends, along with balayage, which is soft, natural highlights, so it doesn't necessitate constant hairstylist visits. Megan believes 'we'll definitely see the lipstick effect come into play,' because 'consumers still want to treat themselves.' During any kind of economic downturn, more and more women begin purchasing lipstick in a bid to reward or treat themselves without breaking the bank. But young women aren't just indulging by buying lipsticks. Megan said they're also purchasing minis and travel sizes of expensive items as well as 'leading the DIY beauty movement.' Young women are using hair glossing kits, press-on nails, lash extensions, self-tanning products, brow lamination kits, and at-home waxing products for salon results without the hefty price tag. Women have been flocking to social media to show off how they do their own lashes at home as they complain about ultra-high salon prices, where lash extensions can cost hundreds a month and thousands a year. Women have been flocking to social media to show off how they do their own lashes at home as they complain about ultra-high salon prices, where lash extensions can cost hundreds a month and thousands a year 'While the costs of goods are rising, consumers will reframe value and view the products they buy not just in terms of price, but in performance, purpose, and practicality,' Megan warned. Megan believes people are going to try more cost-effective beauty techniques, including doing their own hair extensions and spray tans. Young women are buying dupes, not just when it comes to high-end items like bags, but also to try more affordable makeup products. They're flocking to TikTok Shop to buy these inexpensive options when they're not opting for at-home spa days.
CBS News
02-04-2025
- CBS News
Family alleges Plano ISD teacher abused high school student with disability; police investigating
A Plano Independent School District family believes their high school senior, who has a disability, was abused by a teacher. Police are investigating. Lestia Nelson said a few years ago her daughter, Saniyah was diagnosed with a rare genetic disorder called GRIN syndrome. "She's totally disabled," she said. "She needs help with personal care, feeding, transferring, diapering, everything." Nelson said earlier this year, she started noticing things that would concern her when her daughter would arrive home from school. "When she would get home she would have a horrible diaper rash that would be bleeding," she said. "I asked them about it, asked them if they could change her more, and it was a struggle. Also, with the feeding, they put her on a liquid diet without notifying me so Saniyah lost 10-15 pounds." Nelson said she asked her daughter if she could put a recording device in her backpack. "She said yes, so I put an audio recorder in her book bag and just recorded," she said. On January 8, she heard Saniyah crying. "I know that Saniyah doesn't just cry," she said. She took her daughter to a doctor who documented a "decreased range of motion" in her neck. Nelson said her daughter has not returned to school since. She told CBS News Texas she asked Plano ISD to send her the video from that day and just received it last week. A teacher's actions in the video greatly concerned her. "While she was doing something, she elbowed her and pushed her head down and then because Saniyah's head went down, she choked her to pick her up and Saniyah started crying," Nelson said. "I saw that she bent her fingers backward." "It's really difficult to watch the video more than once but each time we do look at it we do find something else that was wrong," Alvin Nelson said. On social media, Lestia Nelson documented all of her concerns. In a statement to CBS News Texas, a spokesperson for Plano ISD said: Plano police confirm they're investigating. Lestia Nelson believes there needs to be more accountability and wants to see criminal charges. "I'm a fighter and I'm going to fight for Sanaya until everything is right," she said.
Yahoo
01-04-2025
- Business
- Yahoo
GRIN Therapeutics Receives Priority Medicines (PRIME) Designation from EMA for Radiprodil in the Treatment of GRIN-Related Neurodevelopmental Disorder
Designation highlights continued regulatory progress and recognizes the potential for radiprodil to address the unmet need to a significant extent in GRIN-related neurodevelopment disorder NEW YORK, April 1, 2025 /PRNewswire/ -- GRIN Therapeutics, Inc., a leader in the development of therapies to treat serious neurodevelopmental disorders, today announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to radiprodil, the company's investigational, potent negative allosteric modulator selectively targeting the N-methyl-D-aspartate receptor subtype 2B (NR2B or GluN2B), for the treatment of GRIN-related neurodevelopmental disorder (NDD). This decision follows the recent announcements that radiprodil was awarded Breakthrough Therapy designation for the treatment of seizures associated with GRIN-related NDD with gain-of-function (GoF) mutations and Orphan Drug designation for the treatment of GRIN-related NDD by the U.S. Food and Drug Administration (FDA) in February and March 2025, respectively. The company remains on track to initiate a global pivotal Phase 3 clinical trial for radiprodil for the treatment of GRIN-related NDD in mid-2025. "The decision by the EMA to award PRIME designation highlights the global unmet need for treatment options for individuals suffering from GRIN-related NDD and our efforts to develop the first selectively targeted treatment for this condition," said Michael A. Panzara, MD, MPH, Chief Medical Officer at Neurvati Neurosciences and GRIN Therapeutics. "We look forward to continuing to work with global regulatory authorities and the patient community to achieve this goal." PRIME designation is granted by the EMA in recognition of priority medicines that have demonstrated the potential to target an unmet need to a significant extent. PRIME provides enhanced support for the development of therapeutic candidates in order to help optimize development plans and speed up the evaluation process so medicines can reach patients earlier. This designation provides drug developers with several benefits, including early appointment of the Committee for Medicinal Products for Human Use (CHMP) Rapporteur, which enables discussion regarding preparation of the marketing authorization application (MAA), enhanced interaction and early dialogue with the EMA. GRIN Therapeutics, which is backed by a $200M capital commitment from Blackstone Life Sciences, remains on track to initiate a global Phase 3 pivotal trial for radiprodil in GRIN-related NDD in mid-2025. The Phase 3 trial will aim to evaluate the impact of targeted treatment on core aspects of the disease, including seizures, behavioral abnormalities and functional outcomes. About GRIN-related neurodevelopmental disorder GRIN-related neurodevelopmental disorder is a family of rare, genetically defined pediatric neurodevelopmental disorders caused by mutations in GRIN genes. While symptoms of GRIN-related neurodevelopmental disorder can present as early as infancy, a diagnosis is often not confirmed until age two or later when a child fails to reach developmental milestones. Individuals may experience developmental delay, intellectual disabilities, epilepsy, muscular hypotonia, movement disorders, spasticity, feeding difficulties and behavioral problems. There are currently no approved therapies for GRIN-related neurodevelopmental disorder. About Radiprodil Radiprodil is an investigational, selective and potent negative allosteric modulator of the N-methyl-D-aspartate (NMDA) receptor subtype 2B (NR2B or GluN2B) that has received Breakthrough Therapy designation and Orphan Drug designation from the U.S. Food and Drug Administration (FDA) as well as Priority Medicines (PRIME) designation from the European Medicines Agency (EMA). In in vitro and in vivo preclinical models, radiprodil has been shown to potently and selectively modulate GluN2B. In 2024, data from the Phase 1b Honeycomb study of radiprodil in pediatric patients with GRIN-related neurodevelopmental disorder and confirmed Gain of Function (GoF) mutations showed that patients in the qualifying seizure cohort experienced a median reduction of 86% in countable motor seizure (CMS) frequency compared to baseline, with 5 of 7 patients seeing greater than 50% reduction. Clinicians and caregivers generally assessed patients as improved clinically over the course of the study regardless of the occurrence of seizures as measured by Clinician and Caregiver Global Impressions of Change (CGI-C and CaGI-C) and the Aberrant Behavior Checklist – Community (ABC-C) scales. In addition, the drug appeared to be generally well tolerated. Adverse events most commonly observed were those associated with infections or underlying disease symptoms. Three patients experienced a serious adverse event associated with infection; all were assessed as unrelated to radiprodil. Radiprodil is also being developed for the treatment of tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD). In vitro analysis of brain tissues extracted from both TSC and FCD lesions has shown enhanced GluN2B NMDA expression supporting the potential ability of radiprodil to control seizures in these conditions. RAD-GRIN-201, also known as the Astroscape study, is an ongoing, open-label Phase 1b/2a trial assessing the safety, tolerability, pharmacokinetics (PK), and potential efficacy of radiprodil in participants with TSC or FCD type II. About GRIN Therapeutics GRIN Therapeutics is dedicated to the research and development of precision therapeutics for pediatric neurodevelopmental disorders with the goal of bringing hope to patients and caregivers. Late last year, GRIN Therapeutics reported promising topline data from a Phase 1b/2a clinical trial (the Honeycomb Trial) evaluating radiprodil in GRIN-related neurodevelopmental disorder in patients with GoF variants, leading to the decision to advance to a Phase 3 trial. The company has an additional ongoing clinical trial to evaluate radiprodil for the potential treatment of tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) type II. GRIN Therapeutics is an affiliate of Neurvati Neurosciences, a portfolio company of Blackstone Life Sciences (BXLS). For more information, please visit About Neurvati Neurosciences Neurvati Neurosciences, a portfolio company of Blackstone Life Sciences, identifies and advances the development of high-potential drug candidates across the neuroscience landscape. Neurvati employs a collaborative model that establishes fit-for-purpose affiliate companies, aligning dedicated resources with long-term strategic capital to catalyze innovative treatment options in areas of unmet need. Neurvati's team of experienced operators and drug developers seeks opportunities to challenge current treatment paradigms and make a difference for patients suffering from a wide range of neurological and psychiatric disorders. For more information, please visit About Blackstone Life Sciences Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within key life science sectors. By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical technologies that improve patients' lives and currently has more than $12 billion in assets under management. Corporate Contact Elliott Ruiz, MBA+1 View original content: SOURCE GRIN Therapeutics Inc. Sign in to access your portfolio
Yahoo
12-03-2025
- Health
- Yahoo
Remarkable Women: Baton Rouge mom helps other parents after losing son to rare disorder
BATON ROUGE, La. (Louisiana First) — A Baton Rouge mom started a nonprofit organization with several other families after losing her only child to a rare disorder. 'Carter absolutely changed my life. He made me a better person, and I think he changed everybody's life that he came into contact with,' CureGRIN Foundation Director of Family & Donor Experience Lauren Williams said. Carter passed away in September 2023 from a rare neurodevelopmental disorder at 7 years old. Williams said her son will always be remembered for his laughter, glasses, and love for outer space. 'He was who he was. GRIN did make him who he was and I never would change that. But if I could have alleviated any of the pain and any of his struggles, I would have done it,' said Williams. Remarkable Women: Sashika Baunchand's organization mentors young Louisiana girls As a new mom, Williams said she immediately noticed something different in her premature newborn before leaving the hospital. Initially, she believed it was just anxiety. When it still didn't sit right with her, she spent hours each day doing research, working as late as 3 a.m. looking for answers. 'It was kind of like he would stare in space like he was in his own little world and no one else existed and so that started me on meeting with different pediatricians to figure out is it just a delay that he'll catch up with, or is it something more than that,' Williams said. After going through nine pediatricians, it turns out Carter was diagnosed with GRIN1, a form of a Glutamate Receptor Ionotropic (GRI) Disorder. Genetic sequencing led to the discovery that he had grown one when he was 1 and a half years old. Williams said connecting with other parents through social media who were experiencing similarities with their child brought relief, comfort, and validation. 'It's one thing to have a community of people who your child share all these symptoms and whatever, but it's another thing to have them have the exact same diagnosis and know, 'Okay, I found my people,' Williams said. Williams and five other groups of parents founded CureGRIN, an organization committed to improving the lives of people living with GRI Disorders. 'I decided it'd be a good idea to have a central hub or a way for people with this diagnosis to have a place to go for resources, knowing somebody is out there advocating for a cure and a treatment, knowing families won't feel so alone,' Williams said. Williams said it's unheard of to go from no research on GRIN1 in 2017 to three clinical trials in 2025. 'It took years as a mom waiting to come home to your child to run up to you. And it took years for him to be able to do that. And it was a moment that has stuck in my brain. And to watch these families be able to experience, 'Oh, my God, I thought my child would not be able to do anything to I can't believe this is happening,'' said Williams. Williams said Carter's passing pushed her towards her purpose to help other parents find answers through CureGRIN. 'It gets me out of bed in the morning, and that's what keeps me going. But seeing Carter, I have him. He's just a part of this house,' said Williams. Today, the CureGRIN Foundation helps over 300 families and has raised over $2 million to support parents and advance research efforts. Globally, there's over 1,000 GRI disorder diagnoses. 'Access to genetic testing is going to show everyone how unrare rare is,' Williams said. Remarkable Women: Baton Rouge mom helps other parents after losing son to rare disorder Missing woman survives 6 days trapped in wrecked car as drivers pass unaware Southern University to build $68M STEM complex, replacing old hall Ascension Parish Schools launch safety campaign ahead of prom season Lone Democrat to back House GOP spending bill explains decision Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
USA Today
31-01-2025
- Entertainment
- USA Today
Puzzle solutions for Friday, Jan. 31, 2025
USA TODAY Note: Most subscribers have some, but not all, of the puzzles that correspond to the following set of solutions for their local newspaper. CROSSWORDS USA TODAY crossword Play the USA TODAY Crossword Puzzle. Los Angeles Times crossword Today's crossword (McMeel) Daily Commuter crossword SUDOKU Play the USA TODAY Sudoku Game. JUMBLE Jumbles: WRING UNCLE ORIGIN ZEALOT Answer: Asking the dog if he had once again ripped up the newspaper was − "RE-TORE-ICAL" (Distributed by Tribune Content Agency) CRYPTOGRAPHY PUZZLES Celebrity Cipher "I don't think comedy is something you learn. I think it's something that's either there or it's not." − Jessica Walter (Distributed by Andrews McMeel) Cryptoquote MUSICIANS DON'T RETIRE; THEY STOP WHEN THERE'S NO MORE MUSIC IN THEM. − LOUIS ARMSTRONG (Distributed by King Features) Cryptoquip WHAT COULD YOU NAME A COMPANY THAT COMES TO PEOPLE'S HOUSES TO CLEAN THEM? "HOME SWEEP HOME." (Distributed by King Features) OTHER PUZZLES Boggle GRIN SMIRK SMILE SNEER SCOWL (Distributed by Tribune Content Agency) Lexigo VISIT, TEXTILE, EXTRA, ARTISTS, STOWAWAY (Distributed by Andrews McMeel) KenKen Scrabblegrams 7 Little Words BULLISHNESS WINDY WORKMAN UNFLAPPABLE ARTIFICIAL BOLE EDWARD (Distributed by Andrews McMeel) Find the Words Riding wind and waves (Distributed by Creators Syndicate) Kubok
